Experimental Diabetes Drugs Offer Patients Hope

By: Associated Press
By: Associated Press

Click on the links below for more information about the diabetes drugs mentioned in the story.

Novo Nordisk's degludec

Lantus

canagliflozin

Drugmakers are presenting results of new studies of experimental diabetes treatments offering patients hope of better controlling blood sugar and weight and preventing dangerously low blood sugar. Those are all big challenges for millions of diabetics.

Results from key studies of several new diabetes drugs and
insulin products are being announced at the American Diabetes
Association conference in Philadelphia.

They include Novo Nordisk's degludec, an ultra-long-acting insulin for Type 2 diabetes that doesn't need to be taken at the same time each day and prevents low blood sugar during the night better than market-leading Lantus.

Johnson & Johnson presented studies on its daily Type 2 diabetes
pill, canagliflozin, part of a new drug class.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
KOLN-TV Call: (402) 467-4321 Toll-free: 1-800-475-1011 840 North 40th Lincoln, NE 68503 Email: info@1011now.com KGIN-TV Call: (308) 382-6100 123 N Locust Street Grand Island, NE 68802 Email: kgin@1011now.com KSNB-TV Toll free 888-475-1011 123 N. Locust St. Grand Island, NE 68802 Email : ksnb@1011now.com
Gray Television, Inc. - Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 158434475 - 1011now.com/a?a=158434475